National Stroke Foundation

Vivlodex (meloxicam)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved October 2015

Specific Treatments:

osteoarthritis pain

Therapeutic Areas

General Information

Vivlodex (meloxicam) is a non-steroidal anti-inflammatory.

Vivlodex is specifically indicated for the management of osteoarthritis pain.

Vivlodex is supplied as a capsule for oral administration. The recommended starting dose is 5 mg orally once daily. The dose may be increased to 10 mg in patients who require additional analgesia. Use the lowest effective dose for shortest duration consistent with individual patient treatment goals.

Clinical Results

FDA Approval

The FDA approval of Vivlodex was supported by data from a Phase III, multi-center, double-blind, placebo-controlled study of 402 patients, aged 40 and older, with pain due to osteoarthritis of the knee or hip, who were randomized to receive treatment with once-daily Vivlodex 5 mg, Vivlodex 10 mg, or placebo over a period of 12 weeks. The Vivlodex doses studied achieved efficacy at 33 percent lower doses than currently available meloxicam products.

Side Effects

Adverse effects associated with the use of Vivlodex may include, but are not limited to, the following:

  • diarrhea
  • nausea
  • abdominal discomfort

Vivlodex comes with a boxed warning of the potential for nonsteroidal anti-inflammatory drugs (NSAIDs) to cause an increased risk of serious cardiovascular and gastrointestinal events.

Mechanism of Action

Vivlodex (meloxicam) is a non-steroidal anti-inflammatory. It has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Vivlodex like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). 

Additional Information

For additional information regarding Vivlodex or osteoarthritis pain, please visit